The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
Hosted on MSN1d
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...
Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...
Burford Brothers Inc. decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 10.6% in the fourth quarter, ...
Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback